April 27 (Reuters) - Indivior Plc raised its revenue forecast for fiscal 2023, but lowered its profit expectations due to operating expenses associated with its buyout of Opiant Pharmaceuticals .
The Opioid addiction treatment maker said it expects annual net revenue to range from $970 million to $1.04 billion. It forecast adjusted operating profit slightly below the previous year's adjusted operating income of $212 million.
(Reporting by Muhammed Husain in Bengaluru; Editing by Devika Syamnath)
((Muhammed.Husain@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments